A double-blind controlled trial of 12 months' treatment with (+)-cyanidanol-3 was carried out in 26 patients with chronic hepatitis B liver disease. Treatment did not improve liver blood tests nor histological appearances of the liver, but there was a trend towards reduction of serum titres of hepatitis B surface antigen.
Introduction
The hepatitis B virus (HBV) is a major cause of chronic liver disease worldwide, and yet no treatment is effective. Initial results of trials of several antiviral agents in patients with HBV chronic liver disease have been disappointing, although it is possible to improve serum virological markers with, for instance, adenine arabinoside, interferon and acyclovir'. Prednisolone may be beneficial in HBe antigen-negative patients2 but this requires confirmation.
Cyanidanol-3 (catechin) is an anti-oxidant flavonoid drug that may improve biochemical tests and the rate of clearance of viruses in acute viral hepati-tis3-', and conflicting trials have suggested that it may also improve the liver blood tests and histology in chronic hepatitis6 IO. We have therefore conducted a double-blind controlled trial of catechin in patients with HBV-associated chronic liver disease, and assessed the titres of serum HB markers, liver blood tests and histology over six months.
Patients and methods
Thirty-five patients entered the trial. On entry all had carried HBsAg for more than six months. None had been on immunosuppressive treatment within six months, and needle liver biopsies had been carried out to confirm chronic liver disease within three months before entry. Patients were stratified according to histological type of liver disease, heteroor homosexuality, and previous treatment. They were randomized to placebo or (+)-cyanidanol-3 (1 g three times daily) for one year.
Each patient was then seen two-monthly for one year, when a second liver biopsy was performed. At each visit a blood sample for liver function tests, viral markers (HBsAg titre, HBeAg and anti-HBe) and routine haematology was taken, and the returned tablets were counted. Patients failing two consecutive attendances or who twice returned more than 10% of the tablets were excluded from the analysis.
The liver biopsy specimens were graded 'blind' by two pathologists according to the international criteria for chronic liver disease into: (a) active chronic hepatitis, (b) chronic persistent hepatitis, and (c) lobular hepatitis, and the presence of cirrhosis was noted.
Results
Twenty-six patients completed the 12-month trial. There were 19 homosexuals, 3 male heterosexuals and 4 female heterosexuals. Initially 15 had active chronic persistent hepatitis, and 2 lobular hepatitis. One had normal histology. One other patient with cirrhosis died from liver failure during the trial and 8 others dropped out or declined a second biopsy. No side effects of treatment were noted. The mean results of liver function tests on entry and at 12 months are shown in Table 1 . There were no differences between the placebo and treatment groups, and there were no significant changes in the haemoglobin or platelet values.
The range of titres of HBsAg was wide, but there was an overall trend in favour of (+)-cyanidanol-3 reducing the titre, especially in active chronic hepatitis, although this was not significant. There was a significant trend for the titres of all groups to improve with time (P<0.05; analysis of variance). Three patients became HBeAg negative and developed HBeAb, 2 clearing HBsAg; all received active treatment.
The histological appearances of the liver biopsy specimens showed no consistent change (14 no change; 7 worse; 5 better).
Discussion
Parenteral or oral administration of cyanidanol may inhibit collagen synthesis and has a potent antiinflammatory action in vitro. Several reports have suggested that cyanidanol increases the elimination of HBV serum markers in patients with acute HBV infection3 5. Thus with its antiviral, anti-inflammatory and immune stimulant properties, cyanidanol might be suitable for the treatment of patients with HBV-associated chronic liver disease, and has few and minor side effects.
There are a few published controlled trials of cyanidanol in chronic liver disease, but their results are contradictory. In the first6 there was some improvement in serum enzymes and liver histology in patients with chronic persistent hepatitis, particularly if HBsAg-negative, but not in active chronic hepatitis. Unfortunately the duration of their disease before entry is not reported. In the second trial7 cyanidanol was more effective than placebo added to corticosteroids in patients with active chronic hepatitis, chiefly HBsAg-negative, although the antigen status was not recorded in all. In a recent trial of. HBsAg-negative active chronic hepatitis there was no beneficial effect of the drug compared to placebo10, while another trial9 in chiefly HBsAg-positive active chronic hepatitis showed a small and non-significant beneficial effect of the drug. In a brief report8 of an enormous study in 338 HBsAg-positive patients in Japan there was some benefit on serum virological markers, but liver blood tests were unaffected.
Although the power of our study was small, it failed to demonstrate any effect of (+)cyanidanol-3 upon liver blood tests or on the morphological appearances of liver biopsy specimens in HBsAg-positive chronic liver disease. There was a small reduction of serum HBsAg titres. At present, therefore, there is no proven effective treatment for HBV-related chronic liver disease.
